These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 9697728

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin.
    Blom J, Heron I, Hendley JO.
    APMIS; 1994 Sep; 102(9):681-9. PubMed ID: 7946271
    [Abstract] [Full Text] [Related]

  • 24. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.
    Berstad AK, Oftung F, Korsvold GE, Haugen IL, Froholm LO, Holst J, Haneberg B.
    Vaccine; 2000 May 08; 18(22):2323-30. PubMed ID: 10738087
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin of Bordetella pertussis in BALB/c Mice.
    Bakhshaei P, Kazemi MH, Golara M, Abdolmaleki S, Khosravi-Eghbal R, Khoshnoodi J, Judaki MA, Salimi V, Douraghi M, Jeddi-Tehrani M, Shokri F.
    J Interferon Cytokine Res; 2018 Apr 08; 38(4):161-170. PubMed ID: 29638208
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB, Huang YY, Halperin SA, Anderson R, Morris A, Macmillan A, Jones T, Burt DS, Van Nest G, Lee SF.
    Clin Exp Immunol; 2006 Jun 08; 144(3):543-51. PubMed ID: 16734625
    [Abstract] [Full Text] [Related]

  • 32. Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo.
    Xing DK, Canthaboo C, Corbel MJ.
    Vaccine; 2000 Apr 14; 18(20):2110-9. PubMed ID: 10715525
    [Abstract] [Full Text] [Related]

  • 33. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.
    Hendrikx LH, Schure RM, Oztürk K, de Rond LG, de Greeff SC, Sanders EA, Berbers GA, Buisman AM.
    Vaccine; 2011 Sep 16; 29(40):6874-80. PubMed ID: 21803088
    [Abstract] [Full Text] [Related]

  • 34. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.
    Ohman L, Willén R, Hultgren OH, Hultgren Hörnquist E.
    Clin Exp Immunol; 2005 Jul 16; 141(1):37-46. PubMed ID: 15958068
    [Abstract] [Full Text] [Related]

  • 35. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.
    Asokanathan C, Corbel M, Xing D.
    Hum Vaccin Immunother; 2013 Feb 16; 9(2):325-31. PubMed ID: 23291942
    [Abstract] [Full Text] [Related]

  • 36. Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.
    Canthaboo C, Xing D, Wei XQ, Corbel MJ.
    Infect Immun; 2002 Feb 16; 70(2):679-84. PubMed ID: 11796599
    [Abstract] [Full Text] [Related]

  • 37. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.
    Clin Infect Dis; 1999 Mar 16; 28(3):552-9. PubMed ID: 10194077
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
    Podda A, Nencioni L, Marsili I, Peppoloni S, Volpini G, Donati D, Di Tommaso A, De Magistris MT, Rappuoli R.
    Vaccine; 1991 Oct 16; 9(10):741-5. PubMed ID: 1759492
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.